Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:ORIC NASDAQ:TVRD NASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.72+1.1%$3.63$1.07▼$4.08$967.81M0.963.02 million shs3.02 million shsORICOric Pharmaceuticals$10.12+1.5%$9.94$3.90▼$14.67$849.68M1.691.16 million shs942,341 shsTVRDTvardi Therapeutics$26.20+0.9%$25.81$8.13▼$34.31$243.01M0.2135,640 shs22,180 shsVERVVerve Therapeutics$11.13$9.30$2.86▼$11.40$992.13M2.233.94 million shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+1.09%+4.49%+2.48%+51.84%+169.57%ORICOric Pharmaceuticals+1.50%-11.54%-4.98%+78.48%-9.64%TVRDTvardi Therapeutics+0.92%-1.21%+22.14%+2,619,999,900.00%+2,619,999,900.00%VERVVerve Therapeutics0.00%-0.67%-0.71%+114.45%+59.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.7291 of 5 stars3.62.00.04.01.80.80.6ORICOric Pharmaceuticals4.5629 of 5 stars4.51.00.04.43.03.30.6TVRDTvardi TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVERVVerve Therapeutics3.3594 of 5 stars4.24.00.00.02.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.7581.45% UpsideORICOric Pharmaceuticals 3.00Buy$18.5783.51% UpsideTVRDTvardi Therapeutics 3.00Buy$64.25145.23% UpsideVERVVerve Therapeutics 2.33Hold$14.5730.92% UpsideCurrent Analyst Ratings BreakdownLatest TVRD, AKBA, ORIC, and VERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025TVRDTvardi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$62.007/11/2025TVRDTvardi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$52.007/8/2025ORICOric PharmaceuticalsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.006/27/2025VERVVerve TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$20.00 ➝ $13.506/26/2025VERVVerve TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/23/2025ORICOric PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.006/18/2025VERVVerve TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$28.00 ➝ $11.006/18/2025VERVVerve TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.006/18/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.506/17/2025VERVVerve TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Market Perform6/17/2025VERVVerve TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$39.00 ➝ $13.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M6.10N/AN/A($0.23) per share-16.17ORICOric PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/ATVRDTvardi Therapeutics$7.14M34.35N/AN/A($3.02) per share-8.68VERVVerve Therapeutics$32.33M30.69N/AN/A$5.83 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.21N/AN/AN/A-24.51%N/A-18.92%8/7/2025 (Estimated)ORICOric Pharmaceuticals-$127.85M-$1.87N/AN/AN/AN/A-51.14%-46.29%8/11/2025 (Estimated)TVRDTvardi Therapeutics-$70.87MN/A0.00∞N/A-595.39%-710.04%-79.00%N/AVERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%8/14/2025 (Estimated)Latest TVRD, AKBA, ORIC, and VERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VERVVerve Therapeutics-$0.70N/AN/AN/A$4.26 millionN/A8/11/2025Q2 2025ORICOric Pharmaceuticals-$0.46N/AN/AN/AN/AN/A8/7/2025Q2 2025AKBAAkebia Therapeutics-$0.02N/AN/AN/A$47.60 millionN/A5/14/2025Q1 2025VERVVerve Therapeutics-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million5/5/2025Q1 2025ORICOric Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.892.232.02ORICOric PharmaceuticalsN/A12.0012.00TVRDTvardi TherapeuticsN/A32.4831.73VERVVerve TherapeuticsN/A9.849.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ORICOric Pharmaceuticals95.05%TVRDTvardi Therapeutics44.66%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%ORICOric Pharmaceuticals6.82%TVRDTvardi Therapeutics3.10%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million254.76 millionOptionableORICOric Pharmaceuticals8085.22 million79.41 millionOptionableTVRDTvardi Therapeutics809.36 million9.07 millionN/AVERVVerve Therapeutics11089.14 million71.94 millionOptionableTVRD, AKBA, ORIC, and VERV HeadlinesRecent News About These CompaniesGSA Capital Partners LLP Buys 78,768 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)3 hours ago | marketbeat.comGene Therapy Companies Set Sights on Cardiovascular DiseaseAugust 1 at 1:15 PM | genengnews.comGY Intercept Hong Kong Ltd Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)July 31 at 4:41 AM | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Receives $14.57 Consensus Target Price from AnalystsJuly 31 at 2:27 AM | americanbankingnews.comCwm LLC Purchases 24,841 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)July 30 at 5:08 AM | marketbeat.comCerity Partners LLC Invests $110,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)July 30 at 5:08 AM | marketbeat.comVerve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102July 29, 2025 | msn.comVerve Therapeutics, Inc. (NASDAQ:VERV) Receives Consensus Rating of "Hold" from AnalystsJuly 28, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Raised to "Hold" at Wall Street ZenJuly 28, 2025 | americanbankingnews.comEli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskJuly 26, 2025 | finanznachrichten.deVerve Therapeutics (NASDAQ:VERV) Upgraded to "Hold" at Wall Street ZenJuly 26, 2025 | marketbeat.comEli Lilly completes acquisition of Verve TherapeuticsJuly 25, 2025 | msn.comLilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskJuly 25, 2025 | prnewswire.comLilly and Verve announce expiration of Verve tender offerJuly 24, 2025 | prnewswire.comPenn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli LillyJuly 24, 2025 | msn.comEli Lilly Advances Pipeline and Gene Focus With Verve AcquisitionJuly 24, 2025 | finance.yahoo.com3 Bullish Biotech Stocks With Explosive Growth Trends...July 21, 2025 | marketbeat.comLilly’s $1 billion CRISPR bet: what Verve means for gene editingJuly 16, 2025 | thepharmaletter.comTGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)...July 15, 2025 | marketbeat.comBiotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.July 14, 2025 | msn.comBiotech Stocks Are Ready to Rebound. 3 to Watch Now.July 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThe Meteoric Rise of Rocket Lab: A Space Stock to WatchBy Ryan Hasson | July 11, 2025View The Meteoric Rise of Rocket Lab: A Space Stock to WatchChipotle: Too Spicy for Smart Money to Resist After Stock SplitBy Jeffrey Neal Johnson | July 11, 2025View Chipotle: Too Spicy for Smart Money to Resist After Stock SplitPepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?By Thomas Hughes | July 19, 2025View PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?Vertical Aerospace Stock Trades at Discount After VX4 MilestoneBy Jeffrey Neal Johnson | July 22, 2025View Vertical Aerospace Stock Trades at Discount After VX4 Milestone3 Infrastructure Stocks Riding the U.S. Building BoomBy Chris Markoch | July 14, 2025View 3 Infrastructure Stocks Riding the U.S. Building BoomTVRD, AKBA, ORIC, and VERV Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.72 +0.04 (+1.09%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.74 +0.02 (+0.54%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Oric Pharmaceuticals NASDAQ:ORIC$10.12 +0.15 (+1.50%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.12 0.00 (0.00%) As of 08/1/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Tvardi Therapeutics NASDAQ:TVRD$26.20 +0.24 (+0.92%) As of 08/1/2025 04:00 PM EasternCara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Verve Therapeutics NASDAQ:VERV$11.13 0.00 (0.00%) As of 07/25/2025Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
